Acrivon Therapeutics announced on April 25, 2025, that it would present data from AP3 Generative Phosphoproteomic analyses of ACR-2316 at the American Association for Cancer Research (AACR) Annual Meeting. The presentation highlighted the molecular mechanisms driving the strong single-agent activity of ACR-2316, a selective WEE1/PKMYT1 inhibitor.
The company reported encouraging early clinical observations from the ongoing Phase 1 monotherapy study of ACR-2316. Dose levels 1, 2, and 3 were cleared without safety concerns or dose-limiting toxicities, and dose level 4 was actively enrolling. Drug target engagement was observed at dose levels 1 and 2 using clinical mass-spectrometry-based AP3 profiling.
Notably, initial clinical activity, including approximately 25% RECIST tumor shrinkage and reduction of metastatic lesions, was observed in a patient at dose level 3. This early evidence of anti-tumor activity at a dose level well below the projected recommended Phase 2 dose supports the potential of ACR-2316 as a monotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.